tim.hodson
Fri, 05/30/2025 – 16:23
May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer.
GE HealthCare’s Cerianna (fluoroestradiol F18) injection, available in the United States, is the only FDA-approved imaging agent for the detection …